Profile data is unavailable for this security.
About the company
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
- Revenue in USD (TTM)0.00
- Net income in USD-9.57m
- Incorporated2007
- Employees21.00
- LocationENDRA Life Sciences Inc3600 Green Ct Ste 350ANN ARBOR 48105-2440United StatesUSA
- Phone+1 (734) 335-0468
- Fax+1 (302) 655-5049
- Websitehttps://www.endrainc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Petros Pharmaceuticals Inc | 4.12m | -20.64m | 3.60m | 21.00 | -- | 0.4323 | -- | 0.8747 | -6.54 | -6.54 | 1.00 | 0.988 | 0.1529 | 0.6795 | 1.89 | 196,223.30 | -26.18 | -32.43 | -39.25 | -68.05 | 70.21 | 62.04 | -171.23 | -201.70 | 1.26 | -- | 0.4539 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -17.23m | 3.62m | 7.00 | -- | -- | -- | -- | -13.51 | -13.51 | 0.00 | -0.9847 | 0.00 | -- | -- | 0.00 | -185.82 | -87.52 | -362.29 | -116.56 | -- | -- | -- | -- | -- | -1,596.37 | -- | -- | -- | -- | 29.84 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -10.44m | 3.64m | 5.00 | -- | 0.4981 | -- | -- | -3.33 | -3.33 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -82.83 | -- | -88.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| Ensysce Biosciences Inc | 1.44m | -11.28m | 3.74m | 7.00 | -- | 1.49 | -- | 2.60 | -2.98 | -2.98 | 0.2845 | 0.2218 | 0.3142 | -- | 8.67 | 205,418.60 | -246.46 | -17.68 | -376.98 | -19.42 | -- | -- | -784.43 | -715.78 | -- | -5.93 | 0.235 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| Avenue Therapeutics Inc | 0.00 | -5.87m | 3.74m | 3.00 | -- | 0.6518 | -- | -- | -3.02 | -3.02 | 0.00 | 4.00 | 0.00 | -- | -- | 0.00 | -177.94 | -186.91 | -- | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -9.57m | 3.83m | 21.00 | -- | 0.034 | -- | -- | -45.63 | -45.63 | 0.00 | 6.21 | 0.00 | -- | -- | 0.00 | -97.17 | -132.00 | -117.34 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| InMed Pharmaceuticals Inc | 5.63m | -6.08m | 3.86m | 13.00 | -- | 0.156 | -- | 0.6863 | -1.23 | -1.23 | 0.9284 | 1.75 | 0.4006 | 2.71 | 29.77 | -- | -43.26 | -88.10 | -50.03 | -104.19 | 39.20 | -- | -108.01 | -1,066.11 | 5.80 | -- | 0.00 | -- | 279.60 | -- | 57.27 | -- | 29.56 | -- |
| Theriva Biologics Inc | 0.00 | -22.27m | 3.91m | 21.00 | -- | 3.28 | -- | -- | -1.25 | -1.25 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -41.30 | -36.95 | -48.49 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -28.37m | 3.93m | 22.00 | -- | 2.10 | -- | -- | -6.49 | -6.49 | 0.00 | 0.6142 | 0.00 | -- | -- | 0.00 | -133.45 | -61.43 | -167.53 | -68.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Ainos Inc | 65.12k | -15.41m | 3.97m | 46.00 | -- | 0.1759 | -- | 60.91 | -3.17 | -3.17 | 0.0126 | 2.80 | 0.0019 | 0.7814 | 13.86 | 1,415.65 | -44.29 | -36.36 | -49.13 | -58.33 | -316.62 | 36.82 | -23,664.28 | -813.63 | 1.45 | -55.50 | 0.4016 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Trevena Inc | 443.00k | -37.03m | 4.01m | 23.00 | -- | -- | -- | 9.05 | -56.17 | -56.17 | 0.6391 | -22.23 | 0.0143 | -- | -- | 19,260.87 | -119.82 | -55.93 | -152.94 | -66.35 | -271.56 | -- | -8,358.24 | -3,134.41 | -- | -20.12 | 2.51 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Helix BioMedix, Inc. | 2.07m | -2.58m | 4.04m | 8.00 | -- | 2.59 | -- | 1.96 | -15.60 | -15.60 | 12.48 | 6.95 | 0.8047 | 1.87 | 4.55 | 258,238.80 | -100.64 | -146.31 | -120.73 | -173.57 | 68.96 | 30.80 | -125.06 | -527.12 | 1.69 | -14.57 | 0.00 | -- | 122.07 | 92.80 | 67.73 | -- | -29.08 | -- |
| Peak Bio Inc | 354.02k | -4.63m | 4.05m | -- | -- | -- | -- | 11.43 | -0.2066 | -0.2066 | 0.0135 | -0.9769 | 0.2192 | -- | -- | -- | -286.54 | -- | -- | -- | -- | -- | -1,307.11 | -- | -- | -4.85 | -- | -- | -39.46 | -- | 2.01 | -- | -- | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.03m | 4.14m | 3.00 | -- | -- | -- | -- | -1.83 | -1.83 | 0.00 | 0.9986 | 0.00 | -- | -- | 0.00 | -139.98 | -104.18 | -163.33 | -111.05 | -- | -- | -- | -- | -- | -563.88 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| Oragenics Inc | 7.47k | -19.52m | 4.16m | 5.00 | -- | -- | -- | 556.41 | -6.99 | -6.99 | 0.0023 | 0.2377 | 0.0013 | -- | -- | 1,494.00 | -349.31 | -97.60 | -451.26 | -106.24 | -- | -- | -261,261.60 | -36,169.75 | -- | -- | 0.00 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
Data as of Sep 20 2024. Currency figures normalised to ENDRA Life Sciences Inc's reporting currency: US Dollar USD
14.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Securities LLCas of 27 Aug 2024 | 146.01k | 10.08% |
| S.H.N. Financial Investments Ltd.as of 04 Jun 2024 | 24.00k | 1.66% |
| L1 Capital Global, Inc.as of 04 Jun 2024 | 24.00k | 1.66% |
| HRT Financial LLCas of 30 Jun 2024 | 6.59k | 0.46% |
| Jane Street Capital LLCas of 30 Jun 2024 | 2.34k | 0.16% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.52k | 0.11% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 796.00 | 0.06% |
| G1 Execution Services LLCas of 30 Jun 2024 | 757.00 | 0.05% |
| Tower Research Capital LLCas of 30 Jun 2024 | 680.00 | 0.05% |
| NewEdge Advisors LLCas of 30 Jun 2024 | 600.00 | 0.04% |
More ▼
Data from 30 Jun 2024 - 29 Aug 2024Source: FactSet Research Systems Inc.
